Mayur Ian Somaiya
Known title: Chief Financial OfficerCIK: 0001760303
Associated companies
Transaction History
| NAMS | ▲ Buy | Option Exercise | 39,784 | $368K | 1/21/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 15,422 | $513K | 1/21/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 24,362 | $823K | 1/21/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 60,216 | $558K | 1/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 900 | $28K | 1/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 39,712 | $1.3M | 1/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 19,604 | $635K | 1/20/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 25,500 | — | 1/7/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 5,118 | $170K | 1/5/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 14,900 | $138K | 1/28/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 3,405 | — | 1/28/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 11,495 | — | 1/28/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 46,983 | $435K | 1/27/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 33,679 | — | 1/27/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 13,304 | — | 1/27/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 38,000 | — | 1/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.